Federal officials on Sept. 9 sent 100 letters to companies telling them to cease misleading advertisements for pharmaceutical products, as President Donald Trump signed a new memorandum saying his administration would “ensure that the current regulatory framework for drug advertising results in fair, balanced, and complete information for American consumers.”
Trump said officials with the Department of Health and Human Services and the Food and Drug Administration (FDA) would take action to make sure that direct-to-consumer ads are transparent, accurate, and not misleading.
